Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579860 | 0.89 | HDAC1 (0.63) | FAAHTSHRKDM4ELMNADRD2 | |
| SCHEMBL8223506 | 0.89 | KDM4E (0.53) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL4581067 | 0.81 | DRD2 (0.48) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL4581057 | 0.81 | DRD2 (0.48) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL4581049 | 0.81 | DRD2 (0.48) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL4580159 | 0.80 | DRD2 (0.57) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL4579632 | 0.76 | HDAC1 (0.72) | — | |
| SCHEMBL3600828 | 0.75 | FAAH (1.00) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL3605147 | 0.75 | FAAH (0.98) | FAAHTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL3593927 | 0.72 | FAAH (1.00) | FAAHTSHRKDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | FAAH 2412/4885TSHR 3869/4885KDM4E 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.